September 12th 2024
The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.
FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
June 7th 2024GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.